Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on January 23, 2026. The filing reports a regulatory milestone regarding its investigational drug, urcosimod (0.05%).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory announcement and contains no financial statements.
Material Changes
There are no financial material changes reported. The significant event is the U.S. Food and Drug Administration (FDA) authorization of a single-patient expanded access (compassionate use) Investigational New Drug (IND) application.
Outlook, Risks, and Management Commentary
- Regulatory Milestone: The FDA authorized the use of urcosimod (0.05%) for a patient with neuropathic corneal pain.
- Investigator: The application was submitted by Pedram Hamrah, MD, at the University of South Florida.
- Legal Status: The announcement is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific clinical indications and patient eligibility criteria for the compassionate use program.
- Confirm the current development stage of urcosimod beyond this single-patient authorization.
- Review the company's most recent Form 20-F for actual financial position and cash runway, as this 6-K contains no financial data.